These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 35434661)

  • 21. Delayed systemic urticarial reactions following mRNA COVID-19 vaccination.
    Pitlick MM; Joshi AY; Gonzalez-Estrada A; Chiarella SE
    Allergy Asthma Proc; 2022 Jan; 43(1):40-43. PubMed ID: 34983709
    [No Abstract]   [Full Text] [Related]  

  • 22. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine - United States, December 21, 2020-January 10, 2021.
    ;
    MMWR Morb Mortal Wkly Rep; 2021 Jan; 70(4):125-129. PubMed ID: 33507892
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.
    Rosenblum HG; Hadler SC; Moulia D; Shimabukuro TT; Su JR; Tepper NK; Ess KC; Woo EJ; Mba-Jonas A; Alimchandani M; Nair N; Klein NP; Hanson KE; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Mbaeyi SA; Oliver SE
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(32):1094-1099. PubMed ID: 34383735
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of Moderna versus Pfizer-BioNTech COVID-19 vaccine outcomes: A target trial emulation study in the U.S. Veterans Affairs healthcare system.
    Ioannou GN; Locke ER; Green PK; Berry K
    EClinicalMedicine; 2022 Mar; 45():101326. PubMed ID: 35261970
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anaphylactic and nonanaphylactic reactions to SARS-CoV-2 vaccines: a systematic review and meta-analysis.
    Alhumaid S; Al Mutair A; Al Alawi Z; Rabaan AA; Tirupathi R; Alomari MA; Alshakhes AS; Alshawi AM; Ahmed GY; Almusabeh HM; Alghareeb TT; Alghuwainem AA; Alsulaiman ZA; Alabdulmuhsin MA; AlBuwaidi EA; Dukhi AKB; Mufti HN; Al-Qahtani M; Dhama K; Al-Tawfiq JA; Al-Omari A
    Allergy Asthma Clin Immunol; 2021 Oct; 17(1):109. PubMed ID: 34656181
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful Treatment of Delayed Localized Necrotizing Inflammatory Myositis After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA-1273 Vaccine: A Case Report.
    Li JC; Siglin J; Marshall MS; Stemmer-Rachamimov A; Bloom SM; Blumenthal KG
    Open Forum Infect Dis; 2022 Oct; 9(10):ofac499. PubMed ID: 36267257
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Advisory Committee on Immunization Practices' Recommendation for Use of Moderna COVID-19 Vaccine in Adults Aged ≥18 Years and Considerations for Extended Intervals for Administration of Primary Series Doses of mRNA COVID-19 Vaccines - United States, February 2022.
    Wallace M; Moulia D; Blain AE; Ricketts EK; Minhaj FS; Link-Gelles R; Curran KG; Hadler SC; Asif A; Godfrey M; Hall E; Fiore A; Meyer S; Su JR; Weintraub E; Oster ME; Shimabukuro TT; Campos-Outcalt D; Morgan RL; Bell BP; Brooks O; Talbot HK; Lee GM; Daley MF; Oliver SE
    MMWR Morb Mortal Wkly Rep; 2022 Mar; 71(11):416-421. PubMed ID: 35298454
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reactogenicity to COVID-19 vaccination in the United States of America.
    Sanyaolu A; Marinkovic A; Prakash S; Desai P; Haider N; Abbasi AF; Mehraban N; Jain I; Ekeh A; Shazley O; Okorie C; Orish VN
    Clin Exp Vaccine Res; 2022 Jan; 11(1):104-115. PubMed ID: 35223671
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pityriasis rosea-like rash after messenger RNA COVID-19 vaccination: A case report and review of the literature.
    Buckley JE; Landis LN; Rapini RP
    JAAD Int; 2022 Jun; 7():164-168. PubMed ID: 35156062
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [A red and swollen arm after vaccination for covid-19].
    De Mik D; Schot LJ; Privé B
    Ned Tijdschr Geneeskd; 2021 Nov; 165():. PubMed ID: 34854640
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial.
    Bonelli M; Mrak D; Tobudic S; Sieghart D; Koblischke M; Mandl P; Kornek B; Simader E; Radner H; Perkmann T; Haslacher H; Mayer M; Hofer P; Redlich K; Husar-Memmer E; Fritsch-Stork R; Thalhammer R; Stiasny K; Winkler S; Smolen JS; Aberle JH; Zeitlinger M; Heinz LX; Aletaha D
    Ann Rheum Dis; 2022 May; 81(5):687-694. PubMed ID: 35027397
    [TBL] [Abstract][Full Text] [Related]  

  • 32. COVID-19 vaccine-related presumed allergic reactions and second dose administration by using a two-step graded protocol.
    Patel GB; Chhiba KD; Chen MM; Guo A; Watts MM; Cullen J; Bochner BS; Grammer LC; Greenberger PA; Saltoun CA; Stevens WW; Kuang FL; Peters AT
    Allergy Asthma Proc; 2021 Nov; 42(6):515-521. PubMed ID: 34871159
    [No Abstract]   [Full Text] [Related]  

  • 33. Bullous drug eruption after second dose of mRNA-1273 (Moderna) COVID-19 vaccine: Case report.
    Kong J; Cuevas-Castillo F; Nassar M; Lei CM; Idrees Z; Fix WC; Halverstam C; Mir A; Elbendary A; Mathew A
    J Infect Public Health; 2021 Oct; 14(10):1392-1394. PubMed ID: 34294590
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines Comirnaty® and COVID-19 mRNA Vaccine Moderna®.
    Speich B; Chammartin F; Smith D; Stoeckle MP; Amico P; Eichenberger AL; Hasse B; Schuurmans MM; Müller T; Tamm M; Dickenmann M; Abela IA; Trkola A; Hirsch HH; Manuel O; Cavassini M; Hemkens LG; Briel M; Mueller NJ; Rauch A; Günthard HF; Koller MT; Bucher HC; Kusejko K;
    Trials; 2021 Oct; 22(1):724. PubMed ID: 34674742
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thrombotic Adverse Events Reported for Moderna, Pfizer and Oxford-AstraZeneca COVID-19 Vaccines: Comparison of Occurrence and Clinical Outcomes in the EudraVigilance Database.
    Tobaiqy M; MacLure K; Elkout H; Stewart D
    Vaccines (Basel); 2021 Nov; 9(11):. PubMed ID: 34835256
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Current state of vaccination against SARS-CoV-2].
    Iking-Konert C; Specker C; Krüger K; Schulze-Koops H; Aries P
    Z Rheumatol; 2021 Mar; 80(2):158-164. PubMed ID: 33528655
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Advisory Committee on Immunization Practices' Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines - United States, 2021.
    Mbaeyi S; Oliver SE; Collins JP; Godfrey M; Goswami ND; Hadler SC; Jones J; Moline H; Moulia D; Reddy S; Schmit K; Wallace M; Chamberland M; Campos-Outcalt D; Morgan RL; Bell BP; Brooks O; Kotton C; Talbot HK; Lee G; Daley MF; Dooling K
    MMWR Morb Mortal Wkly Rep; 2021 Nov; 70(44):1545-1552. PubMed ID: 34735422
    [TBL] [Abstract][Full Text] [Related]  

  • 39. mRNA Covid-19 vaccines in pregnancy: A systematic review.
    Pratama NR; Wafa IA; Budi DS; Putra M; Wardhana MP; Wungu CDK
    PLoS One; 2022; 17(2):e0261350. PubMed ID: 35108277
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects.
    Wheeler SE; Shurin GV; Yost M; Anderson A; Pinto L; Wells A; Shurin MR
    Microbiol Spectr; 2021 Sep; 9(1):e0034121. PubMed ID: 34346750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.